Firefly Neuroscience

Firefly Neuroscience Utilizes Advances in Computational and Artificial Intelligence to Deconstruct, Analyze, and Compare EEGs, Making It Clinically Meaningful for Frontline Clinicians to Objectively Measure, Monitor, and Manage Brain Function. Building on Over a Decade of Research, the Product Has Received FDA Approval and Has Been Commercialized in U.S. Clinics Since Mid-2022. With BNA™, Clinicians and Their Patients Can Now Make Informed, Objective Treatment and Disease Management Decisions, Track Changes Over Time, and Improve Treatment Adherence. Firefly Neuroscience’s AI Platform ("Fly-AI") Has Been Developed to Create Future Biomarkers and Aids for Diagnosis.